Compact pharmaceutical factories can make selected medicines close to where they are needed, but they are not universal drug-printing machines. Research systems have demonstrated liquid medicines and tablets, and a US government report says a modular platform was deployed at a Mississippi medical center in 2025. Each product still requires suitable inputs, a validated process, quality controls and regulatory authorization.
How can a small factory make medicine on demand?
These systems combine some or all of the steps used to turn pharmaceutical ingredients into a finished dosage form. Depending on the design, that can include chemical synthesis, purification, filtration, drying and formulation—or it can begin with an already-made active pharmaceutical ingredient (API) and focus on producing a finished dose.
As an Amazon Associate I earn from qualifying purchases.
“On demand” describes the aim of making selected medicines in smaller quantities, closer to the point of use, rather than relying only on large centralized production. It does not mean any medicine can be made immediately at any location. A factory must be configured and validated for the product and process, supplied with appropriate materials, and operated under controls that establish the finished medicine’s identity, strength and quality.
Recommended Free Tools
What have compact systems actually demonstrated?
The two MIT examples demonstrate different approaches, products and outputs; they are not versions of the same machine. A separate government-reported deployment offers evidence of a platform used outside a research demonstration, but does not establish performance across other sites.
#1 Best Overall
| System and report | What it made and required | Reported scale or deployment |
|---|---|---|
| MIT flow-based system, 2016 | Solutions or suspensions of Benadryl, lidocaine, Valium and Prozac. The reported process integrated synthesis, purification, filtration, drying and final formulation, with ultrasound monitoring used to check concentration. | About 1,000 doses of a given drug in 24 hours, as reported by MIT in 2016. |
| Compact automated tablet system, 2018 peer-reviewed study | Tablets made from drug crystals; the study demonstrated ibuprofen and diazepam and reported that each met US Pharmacopeia standards. | Hundreds to thousands of tablets per day. The reported machine measured 72.4 × 53.3 × 134.6 cm. |
| Pharmacy on Demand (PoD), reported by HHS/ASPR in August 2025 | A modular platform deployed to Northern Mississippi Medical Center to produce medicines in shortage in real time. The report describes federal support for domestic API and finished-dose capacity. | HHS/ASPR said the platform could be as large as a tractor trailer. The report does not provide a comparable dose-per-day figure. |
The MIT figures describe specific demonstrations, not a standard production rate for compact factories generally. The tablet study began with drug crystals; it should not be read as evidence that its unit also synthesized those drugs from chemical starting materials.
Can one machine make different drugs?
Some platforms are designed to be reconfigured, but “different drugs” can mean different products, dosage forms, recipes or manufacturing modules. Changing products may require different inputs, equipment arrangements and process validation. Demonstrating several selected products does not prove that a machine can safely switch to any medicine or change products without preparation.
The point-of-care approach described by NIST illustrates another model: API material is produced centrally under rigorous good manufacturing practice (GMP) controls, then supplied to local sites such as hospitals or pharmacies for personalized-dose production. In that model, the local unit does not necessarily perform chemical synthesis. Its controls still need to check input material, monitor the amount dispensed and verify the finished dose’s quality and quantity.
Quick wins for a faster PC:
Scan for outdated or missing drivers - takes under a minuteDriver Scan →Clear out junk files and repair common Windows errorsFree Scan →Could a hospital make medicines during a shortage?
Potentially, for selected medicines and under an appropriate operating and regulatory framework. In August 2025, the US Department of Health and Human Services’ Administration for Strategic Preparedness and Response (HHS/ASPR) reported that On Demand Pharmaceuticals’ PoD platform had been deployed to Northern Mississippi Medical Center to produce medicines in shortage in real time. That is a reported deployment—not evidence that the same capability is available at every hospital, that the platform is generally for sale, or that it has independently demonstrated the same results at multiple sites.
The rationale is resilience: smaller or distributed manufacturing capacity could provide another source of supply when conventional production is disrupted. MIT professor Allan Myerson described the intended role of the early system as “the emergency backup for pharmaceutical manufacturing,” adding that it was meant to provide an alternative for special situations, not replace traditional manufacturing.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What quality and regulatory controls are needed?
Moving production closer to patients does not remove the need to control the manufacturing process or the finished medicine. FDA identifies advanced manufacturing approaches—including continuous manufacturing, modularization and point-of-care opportunities—as ways that may improve quality, efficiency, shortage response or time to market. Its discussion of flexible networks of smaller sites also frames them as potential reserve capacity.
Rank #4
- Process control: The manufacturing steps and their operating conditions must be controlled and validated for the product.
- Material and dose checks: Inputs, dispensed quantities and finished-product quality need appropriate verification. NIST’s work addresses measurement science, process controls, uncertainty and analytical verification.
- Documentation and oversight: A distributed site still needs a quality system and the required regulatory authorization for its role in making medicines.
Regulatory frameworks are evolving, and the status of a policy document matters. FDA’s 2022 paper on distributed and point-of-care manufacturing is a discussion paper for stakeholder input; FDA explicitly says it is not draft or final guidance and does not convey current requirements or policy. FDA’s FRAME initiative page lists a proposed rule issued in July 2026 concerning registration and listing requirements for establishments engaged in distributed manufacturing. It is proposed, not a final rule. Separately, the UK government’s 2025 overview describes that jurisdiction’s licensing framework for modular manufacture and point-of-care medicinal products, including approved units and sites, manufacturing controls, GMP and master files. Those UK provisions should not be treated as US law.
Quick Recap
Best Value
What compact pharmaceutical factories do—and do not—mean
- They are a family of manufacturing approaches, not one universal machine.
- Research demonstrations show that selected liquids and tablets can be produced on compact systems, with different inputs and reported output rates.
- A government-reported deployment shows a modular platform being used at one medical center, but does not establish broad availability or performance at other sites.
- “On demand” changes where and how selected medicines may be made; it does not bypass validation, quality assurance or regulatory oversight.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
